Skip to main content
AI Market Summary
Loading market intelligence...

Global Blood Therapeutics Inc. (GBT) Stock Forecast 2025 - AI Price Prediction & Analysis


Global Blood Therapeutics Inc. (GBT) AI Stock Price Forecast & Investment Analysis

Global Blood Therapeutics Inc. Stock Price Chart and Technical Analysis

Loading Global Blood Therapeutics Inc. interactive price chart and technical analysis...

Global Blood Therapeutics Inc. (GBT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Global Blood Therapeutics Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Global Blood Therapeutics Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Global Blood Therapeutics Inc.: Global Blood Therapeutics Inc. operates in the Manufacturing sector, establishing it as a mid-cap growth opportunity.

Global Blood Therapeutics Inc. (Stock Symbol: GBT) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.

The organization employs approximately 389 professionals worldwide and operates under the strategic leadership of CEO Ted Love.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Global Blood Therapeutics Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Global Blood Therapeutics Inc.: With $211M in annual revenue and -146.8% net margin, the company demonstrates developing profitability.

Annual Revenue: $211 million generating a -146.8% net profit margin .

Market Capitalization: $4608 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -124.5% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Global Blood Therapeutics Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Global Blood Therapeutics Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Global Blood Therapeutics Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Global Blood Therapeutics Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Global Blood Therapeutics Inc.: Market positioning analysis based on available financial and operational metrics.

Global Blood Therapeutics Inc. strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy 98.2% gross margin, indicating strong pricing power and operational efficiency.

Global Blood Therapeutics Inc. (GBT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Global Blood Therapeutics Inc. stock analysis.

Loading Global Blood Therapeutics Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Global Blood Therapeutics Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Global Blood Therapeutics Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Global Blood Therapeutics Inc.: With a P/E ratio of -6.36, the market sees the stock as potentially undervalued.

P/E Ratio -6.36x
P/B Ratio 38.93x
Market Cap $4608M
EPS $-4.86
Book Value/Share $1.76
Revenue/Share $3.30
FCF/Share $-3.86
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Global Blood Therapeutics Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Global Blood Therapeutics Inc.: An ROE of -124.5% indicates room for improvement in shareholder value creation.

ROE -124.5%
ROA -40.8%
ROIC -43.0%
Gross Margin 98.2%
Operating Margin -137.3%
Net Margin -146.8%
EBT Margin -146.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Global Blood Therapeutics Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Global Blood Therapeutics Inc.: A current ratio of 8.52 indicates strong liquidity.

Current Ratio 8.52x
Quick Ratio 7.33x
D/E Ratio 4.87x
Financial Leverage 6.48x
Interest Coverage -14.5x
Working Capital $553M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Global Blood Therapeutics Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Global Blood Therapeutics Inc.: Free cash flow of $-252M indicates cash challenges that need attention.

Operating Cash Flow $-249M
Free Cash Flow $-252M
Capital Spending $-2M
FCF/Sales -119.4%
CapEx/Sales 1.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Global Blood Therapeutics Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Global Blood Therapeutics Inc.: An asset turnover of 0.28x suggests room for improvement in asset utilization.

Asset Turnover 0.28x
Receivables Turnover 9.2x
Inventory Turnover 0.1x
Fixed Assets Turnover 2.5x
Days Sales Outstanding 40 days
Days Inventory 5023 days
Payables Period 761 days
Cash Conversion Cycle 4302 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Global Blood Therapeutics Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Global Blood Therapeutics Inc.: With annual revenue of $211M, Global Blood Therapeutics Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $211M
Operating Income $-299M
Net Income $-310M
R&D Expense $227M
SG&A Expense $134M
Cost of Goods Sold $4M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 78%
Cash & Short-term Investments 64%
Total Liabilities 85%
Accounts Receivable 3%
Inventory 7%
Dividend & Shareholder Information
Shares Outstanding 67M

Latest Global Blood Therapeutics Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Global Blood Therapeutics Inc. (GBT) stock price and investment outlook.

, source: Benzinga.com

The 90 mg GBT440 data presented by Global Blood Therapeutics Inc (NASDAQ: GBT) at the American Society of Hematology meeting showed “consistent and durable responses”. Wedbush’s Heather Behanna ...

, source: Law

Pfizer subsidiary Global Blood Therapeutics was hit with a personal injury lawsuit on Sept. 16 in California Superior Court for San Mateo County over their sickle cell disease drug Oxbryta. The action ...

, source: Reuters

* Global Blood Therapeutics - continue to expect cash,cash equivalents,marketable securities to be enough to take co to top-line data in hope study * Global Blood Therapeutics Inc - ‍qtrly cash, cash ...

, source: Fox2Now St. Louis

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said Monday ...

Global Blood Therapeutics Inc. Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Global Blood Therapeutics Inc. against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Global Blood Therapeutics Inc. Stock Forecast

How accurate are Global Blood Therapeutics Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for GBT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Global Blood Therapeutics Inc. stock price forecasts?

Our analysis considers Global Blood Therapeutics Inc.'s financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Global Blood Therapeutics Inc. a good investment in 2025?

Based on our AI analysis, Global Blood Therapeutics Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Global Blood Therapeutics Inc. forecasts updated?

Global Blood Therapeutics Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Global Blood Therapeutics Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Global Blood Therapeutics Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...